Insightful Backbone Modifications Preventing Proteolytic Degradation of Neurotensin Analogs Improve NT<i>S1</i>-Induced Protective Hypothermia.
Backbone modifications in NT(8-13) analogs improve stability and hypothermic efficacy, highlighting potential for neuroprotective applications.
Where it sits
this study against the rest of the abs-201 corpusSummary and findings
This study investigated the effects of backbone modifications on the stability and hypothermic efficacy of Neurotensin analogs in a preclinical setting. Modified NT(8-13) analogs demonstrated improved resistance to proteolytic degradation and sustained hypothermic effects. The results suggest that increased peptide stability, rather than receptor binding affinity, drives the hypothermic response.
Abstract
Therapeutic hypothermia represents a brain-protective strategy for multiple emergency situations, such as stroke or traumatic injury. Neurotensin (NT), which exerts its effects through activation of two G protein-coupled receptors, namely NTS1 and NTS2, induces a strong and long-lasting decrease in core body temperature after its central administration. Growing evidence demonstrates that NTS1 is the receptor subtype mediating the hypothermic action of NT. As such, potent NTS1 agonists designed on the basis of the minimal C-terminal NT(8-13) bioactive fragment have been shown to produce mild hypothermia and exert neuroprotective effects under various clinically relevant conditions. The high susceptibility of NT(8-13) to protease degradation (half-life <2 min) represents, however, a serious limitation for its use in pharmacological therapy. In light of this, we report here a structure-activity relationship study in which pairs of NT(8-13) analogs have been developed, based on the incorporation of a reduced Lys<sup>8</sup>-Lys<sup>9</sup> bond. To further stabilize the peptide bonds, a panel of backbone modifications was also inserted along the peptide sequence, including Sip<sup>10</sup>, D-Trp<sup>11</sup>, Dmt<sup>11</sup>, Tle<sup>12</sup>, and TMSAla<sup>13</sup>. Our results revealed that the combination of appropriate chemical modifications leads to compounds exhibiting improved resistance to proteolytic cleavages (>24 h; <b>16</b>). Among them, the NT(8-13) analogs harboring the reduced amine bond combined with the unnatural amino acids TMSAla<sup>13</sup> (<b>4</b>) and Sip<sup>10</sup> (<b>6</b>) or the di-substitution Lys<sup>11</sup> - TMSAla<sup>13</sup> (<b>12</b>), D-Trp<sup>11</sup>-TMSAla<sup>13</sup> (<b>14</b>), and Dmt<sup>11</sup>-Tle<sup>12</sup> (<b>16</b>) produced sustained hypothermic effects (-3°C for at least 1 h). Importantly, we observed that hypothermia was mainly driven by the increased stability of the NT(8-13) derivatives, instead of the high binding-affinity at NTS1. Altogether, these results reveal the importance of the reduced amine bond in optimizing the metabolic properties of the NT(8-13) peptide and support the development of stable NTS1 agonists as first drug candidate in neuroprotective hypothermia.
Background
Therapeutic hypothermia is a strategy used to protect the brain in emergency situations like stroke or traumatic injury. Neurotensin (NT) is known to induce hypothermia through activation of its receptors, primarily NTS1. However, the NT(8-13) fragment is rapidly degraded by proteases, limiting its therapeutic potential. This study explores modifications to enhance the stability and efficacy of NT(8-13) analogs.
Methods
The study involved a structure-activity relationship analysis of NT(8-13) analogs with various backbone modifications. These modifications included a reduced Lys8-Lys9 bond and substitutions with unnatural amino acids like TMSAla13 and Sip10. The primary outcome was the resistance to proteolytic degradation and the secondary outcome was the hypothermic effect.
Results
The modified NT(8-13) analogs exhibited improved resistance to proteolytic degradation, with stability exceeding 24 hours. The analogs also produced a sustained hypothermic effect of -3°C for at least 1 hour. The enhanced hypothermia was attributed to increased peptide stability rather than high receptor binding affinity.
Interpretation
The findings suggest that backbone modifications can significantly enhance the stability and hypothermic efficacy of NT(8-13) analogs. While the results are promising, they are limited to preclinical models, and further research is needed to assess clinical relevance. The study supports the potential for developing stable NTS1 agonists for neuroprotective hypothermia.
Key findings
- Proteolytic resistance improved to >24 hours.
- Sustained hypothermic effect of -3°C for at least 1 hour.
- NT(8-13) analogs with TMSAla13 and Sip10 modifications showed notable effects.
- Hypothermia driven by peptide stability, not high NTS1 binding-affinity.
Limitations
- Preclinical study, not directly applicable to humans
- No human data available
- Limited to in vitro and animal models